NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT05226871 2025-11-25Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesPfizerPhase 2 Active not recruiting35 enrolled
NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled
NCT02627274 2022-11-22A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)Hoffmann-La RochePhase 1 Completed134 enrolled
NCT03552406 2021-05-06Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid TumorsISU Abxis Co., Ltd.Phase 1 Unknown33 enrolled
NCT00622674 2017-12-02Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsMasonic Cancer Center, University of MinnesotaPhase 1 Completed37 enrolled
NCT01451632 2016-09-08A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersMerrimack PharmaceuticalsPhase 1 Completed48 enrolled 14 charts